Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Maureen Genov

Physician Assistant Pearland, TX Physician Assistant

NPI 1396368015 CMS profile 10576210

9223 Broadway St Ste 103, Pearland, TX 77584

Open in the dashboard

General payments

$15,086

580 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Maureen Genov of Pearland, TX is reported in the CMS Open Payments database as having received $15,086 across 580 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,514 45
2024 General $2,441 73
2023 General $4,761 199
2022 General $4,287 184
2021 General $2,083 79

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Maureen Genov
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Maureen Genov were reported at $1,514. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Maureen Genov Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $2,083 $132 $37–$438 $132
2022 $4,287 $155 $48–$522 $149
2023 $4,761 $167 $52–$557 $160
2024 $2,441 $178 $55–$600 $164
2025 $1,514 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $2,429 58 payments
  2. GlaxoSmithKline, LLC. $2,265 118 payments
  3. Regeneron Healthcare Solutions, Inc. $1,566 47 payments
  4. Genzyme Corporation $1,287 23 payments
  5. CSL Behring $845 43 payments
  6. Genentech USA, Inc. $768 35 payments
  7. Novartis Pharmaceuticals Corporation $723 36 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $597 26 payments
  9. OptiNose US, Inc. $553 21 payments
  10. Incyte Corporation $510 21 payments
  11. Other $3,542 152 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $14,896 577 payments
  2. Education $190 3 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT Immunology $1,943 53 payments
  2. DUPIXENT Inflammation And Immunology $1,526 45 payments
  3. TEZSPIRE $1,053 17 payments
  4. TRELEGY ELLIPTA $1,052 68 payments
  5. FASENRA $1,035 24 payments
  6. NUCALA $738 46 payments
  7. Xolair Immunology $731 35 payments
  8. XOLAIR Pulmonary/Respiratory Diseases $580 30 payments
  9. Xhance $553 21 payments
  10. CUVITRU $527 23 payments
  11. Other $6,212 282 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

140

Median for Physician Assistant: 241

Drug cost

$51,050

Median for Physician Assistant: $4,110

Branded share of claims

45%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xolair Omalizumab Brand 11 $30,469
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 23 $18,806
Fluticasone Propionate Generic 30 $525
Azelastine Hcl Generic 13 $481
Albuterol Sulfate Hfa Albuterol Sulfate Brand 17 $397
Montelukast Sodium Generic 23 $214
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 12 $150
Prednisone Generic 11 $6

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$1,380

Medicare's payments for the services billed

Medicare patients

34

Average age 69

Services billed

83

21 women, 13 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 71%
Heart failure 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $459
  • Regeneron Healthcare Solutions, Inc. $167
  • SANOFI-AVENTIS U.S. LLC $82
$709 — —
XOLAIR
  • Novartis Pharmaceuticals Corporation $189
  • Genentech USA, Inc. $115
  • Genentech, Inc. $20
$325 11 —
NUCALA
  • GlaxoSmithKline, LLC. $211
$211 — —
AREXVY
  • GlaxoSmithKline, LLC. $181
$181 — —
RINVOQ
  • AbbVie, Inc. $157
$157 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

580 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record